-
Shanghai Pharmaceuticals’ MediTrust Health Partners with Eisai for Comprehensive Patient Services
•
Shanghai Pharmaceuticals Holding Co., Ltd’s (HKG: 2607, SHA: 601607) subsidiary, MediTrust Health, which specializes in insurance, financing, and direct-to-patient pharmacy services, has entered into a strategic partnership with Japanese pharmaceutical company Eisai (TYO: 4523). This collaboration grants Eisai access to MediTrust Health’s “One-Code Direct Payment-Diversified Payment Platform,” aiming to establish…
-
Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE
•
At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607) announced a series of partnerships with prominent pharmaceutical companies, spanning domestic and international entities. Expanding Collaborations in Pharmaceutical InnovationFrance’s Sanofi (NASDAQ: SNY) has agreed to deepen its existing partnership with SPH, initially…
-
Novartis Forges Partnerships at CIIE to Strengthen Radioligand Therapy Ecosystem in China
•
At the 7th China International Import Expo (CIIE), Swiss pharmaceutical giant Novartis (NYSE: NVS) announced strategic partnerships with US medical device and life sciences company GE Healthcare Technologies Inc., (NASDAQ: GEHC), and Chinese firms Shanghai Pharmaceuticals Holding Co., Ltd (HKG: 2607, SHA: 601607; SPH) and C.Q. Pharmaceutical Holding Co., Ltd…
-
Shanghai Pharmaceuticals Reports Q3 2024 Revenue Growth, Strengthens Drug Pipeline
•
China’s Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced its financial results for the third quarter of 2024, reporting a total revenue increase of 6.14% year-on-year (YOY) to RMB 209.629 billion (USD 29.42 billion). The pharmaceutical industry and pharmaceutical business segments achieved sales of RMB 18.284 billion (USD 2.56…
-
Bayer AG Launches China Innovation Hub to Boost Local R&D and Global Integration
•
Bayer AG (ETR: BAYN), a German multinational pharmaceutical and life sciences giant, has announced the launch of the China Center of Innovation and Partnership (CIIP) at the SH-INNO incubator in Shanghai. The incubator, established in August this year, is a collaborative effort between Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607),…
-
Shanghai Pharmaceuticals Partners with SIBPT to Boost Biopharmaceutical R&D and Translation
•
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a partnership with the Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), formerly known as the Shanghai Institute of Planned Parenthood Research (SIPPR). The collaboration aims to enhance collaboration in scientific research and development, achievement translation, team building, and party…
-
Pfizer Partners with Shanghai Pharmaceutical for Long-Term Vaccine Collaboration in China
•
Pfizer Inc. (NSE: PFIZER, NYSE: PFE, ETR: PFE), a leading pharmaceutical company in the U.S., has entered into a partnership with China’s Shanghai Pharmaceutical Holding Co., Ltd (SHA: 601607; SPH) to establish a long-term collaboration in the vaccine sector. The collaboration will focus on product promotion, introduction of innovative products,…
-
Shanghai Pharmaceuticals’ Dual-Targeting CAR-T Therapy Advances with IND Re-Acceptance
•
Shanghai Pharmaceuticals Group Co., Ltd. (SHA: 601607)’s biotech subsidiary has announced that its investigational ‘CD19 and CD22 targeting chimeric antigen receptor T cell injection’ has received renewed acceptance for its Investigational New Drug (IND) application by the relevant authorities. Known under the development code B019, this cellular therapy candidate has…
-
Shanghai Pharmaceuticals Posts 5.14% YOY Revenue Growth in 2024H1 with Focus on Cell Therapies
•
Shanghai Pharmaceuticals Holding Co. (SPH; HKG: 2607; SHA: 601607) has announced its financial results for the first half of 2024, reporting a 5.14% year-on-year (YOY) increase in revenues, which reached RMB 139.413 billion. The pharmaceutical industry sector saw a decline in revenue, with a 13.37% YOY decrease to RMB 12.734…
-
Shanghai Pharmaceuticals’ SH-INNO Incubator to Drive Biopharmaceutical Innovation and Collaboration
•
Shanghai Pharmaceuticals (SPH;HKG: 2607; SHA: 601607) has launched the “SH-INNO incubator,” a collaborative initiative with premier academic institutions and leading scientific research organizations. The incubator is designed to dismantle conventional silos and foster interdisciplinary collaboration among professionals, scholars, corporations, and financiers across the spectrum of “industry, academia, research, medicine, and…
-
Shanghai Pharmaceuticals Secures NMPA Nod for Roche’s Valcyte Generic
•
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its generic version of Roche’s Valcyte (valganciclovir). Valganciclovir is a crucial medication primarily used to treat cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS)…
-
Shanghai Pharmaceuticals’ Subsidiary Shaphar Med Collaborates with Magic Med to Enter Oncology
•
Shanghai Pharmaceuticals Holding Co., Ltd (SPH, SHA: 601607; HKG: 2607), a leading pharmaceutical company in China, has announced that its subsidiary, Shaphar Medical Instruments (Shanghai) Co., Ltd, has entered into a partnership with Magic Med, a Chinese firm. This strategic collaboration signifies Shaphar Med’s inaugural venture into the oncology sector.…
-
Shanghai Pharmaceuticals Halts Development of B001 and I022 for Selected Indications
•
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced the discontinuation of clinical studies and further development for its drug candidates B001, B001-A, I022, and I022-K. B001, a monoclonal antibody (mAb) intended for the treatment of CD20-positive B-cell non-Hodgkin’s lymphoma (B-NHL), has been suspended following the completion of Phase I,…
-
Shanghai Pharmaceuticals, SHC, and CEMCS CAS Renew Partnership to Incubate Pharmaceutical Innovations
•
Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, SHA: 601607; HKG: 2607), a leading pharmaceutical company in China, has renewed its partnership with Shanghai Healthcare Capital (SHC) and the Center for Excellence in Molecular Cell Science of the Chinese Academy of Sciences (CEMCS, CAS). The trio initially agreed to establish an innovative…
-
Shanghai Pharmaceuticals Appoints New Chairman Amid Leadership Shake-up
•
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), one of the leading pharmaceutical giants in China, has announced significant leadership changes. Yang Qiuhua has been appointed as the new Chairman of the 8th Board of Directors, following the resignation of the former acting chairman, Yao Jiayong. Yao has stepped down from…
-
Shanghai BDgene Partners with SPH RD to Advance Gene Therapy Development
•
Shanghai BDgene Technology Co., Ltd., a China-based specialist in gene therapy, has entered into a strategic partnership with SPH RD, a wholly owned subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607, HKG: 2607). This collaboration aims to leverage BDgene’s advanced carrier technology and gene therapy R&D achievements alongside SPH…
-
Shanghai Pharmaceuticals’ MediTrust Health Teams Up with Eisai to Enhance Alzheimer’s Prevention and Treatment
•
Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607, HKG: 2607)’s subsidiary MediTrust Health, which specializes in insurance, financing, and direct-to-patient pharmacy services, has entered into a partnership with Japan’s Eisai to jointly address the prevention, control, and security of Alzheimer’s disease (AD). The collaboration aims to develop a comprehensive health management…
-
Shanghai Pharmaceuticals and HKSTPC Launch 01LABS@Hong Kong Incubator
•
01LABS@Hong Kong, a Shanghai-Hong Kong innovation incubator, has officially commenced operations. The incubator was jointly established by China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607; HKG: 2607; SPH), Shanghai Biopharmaceutical Frontier Industry Innovation Center Co., Ltd, a subsidiary of SPH, and the Hong Kong Science & Technology Parks Corporation (HKSTPC).…
-
Synvida Raises Nearly RMB 200 Million in Series A Funding to Advance Clinical Studies
•
Synvida, a biotech company incubated by Shanghai Pharma (HKG: 2607, SHA: 601607) and Shanghai Healthcare Capital (SHC), has reportedly secured nearly RMB 200 million (approximately USD 28 million) in a Series A financing round led by Lapam Capital, with participation from SHC. The funds will be allocated to clinical and…
-
Shanghai Pharmaceuticals’ Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate
•
The Shanghai Administration for Market Regulation (AMR) bureau has once again reprimanded SHP No.1 Biomedical & Pharmaceutical Co., Ltd., a wholly owned subsidiary of Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), for monopolistic pricing practices, this time concerning the injection product polymyxin B sulfate. The Chinese company has pledged to…
-
Shanghai Pharmaceuticals and Sanofi Broaden Collaboration to Include Nationwide Disease Management
•
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) , a leading pharmaceutical company based in China, has entered into a comprehensive partnership with the French pharmaceutical giant Sanofi (NASDAQ: SNY). The collaboration aims to address major disease areas on a nationwide scale, establishing an end-to-end value chain system that spans from…
-
Shanghai Pharmaceuticals Hit with Anti-Monopoly Fine by Shanghai Market Supervision Bureau
•
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company based in China, has recently come under regulatory scrutiny. Following the earlier reports that C-suite executives were under investigation, the company has now announced receiving an Administrative Penalty Decision letter from Shanghai’s Market Supervision Administration regarding its wholly-owned…
-
Shanghai Pharmaceuticals Gains NMPA Approval for WST04 Clinical Trials in Oncology
•
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has received clinical trial approval from the National Medical Products Administration (NMPA) for its oral probiotic preparation, WST04, aimed at treating advanced malignant solid tumors. Preclinical studies indicate that WST04 significantly enhances the anti-tumor efficacy of…
-
Shanghai Pharmaceuticals’ Chairman Zhou Jun Resigns Amid Investigation
•
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading Chinese pharmaceutical distribution company, has announced the resignation of Zhou Jun from his roles as chairman, non-executive director, convener, and committee member of the Strategy Committee of the Board of Directors. Zhou cites personal reasons for his departure and will not…
-
Chiesi Farmaceutici and Shanghai Pharmaceutical Partner on Distribution at CIIE
•
Among the series of deals secured by multinational corporations at the 6th China International Import Expo (CIIE), Italy-based Chiesi Farmaceutici S.p.A. has inked a partnership with Shanghai Pharmaceuticals Co., Ltd (SHA: 601607, HKG: 2607). This strategic alliance aims to capitalize on Shanghai Pharmaceutical’s extensive distribution network. As reported by Shine,…
-
Eisai Partners with Shanghai Pharmaceuticals for Alzheimer’s Drug Leqembi in China
•
Eisai (TYO: 4523), a Japan-headquartered pharmaceutical company, has entered into a significant partnership with Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading China-based pharmaceutical distribution giant, to collaborate on the Alzheimer’s disease (AD) drug Leqembi (lecanemab). The deal is potentially valued at RMB 1.5 billion (USD 205 million) and…
-
Bayer and Shanghai Pharmaceuticals Launch Co.Lab to Incubate Life Sciences Innovation in China
•
Bayer, the Germany-headquartered multinational pharmaceutical and life sciences company (ETR: BAYN), has entered into a partnership with Shanghai Pharmaceuticals, a leading China-based pharmaceutical distribution giant (SPH; HKG: 2607; SHA: 601607), to co-construct a new life sciences incubator named Co.Lab. This collaboration is designed to foster cutting-edge innovation in cell and…
-
Shanghai Pharmaceuticals Gets NMPA Approval for Phase I Clinical Study of B019 CAR-T Cell Injection
•
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has received approval from the National Medical Products Administration (NMPA) to commence a Phase I clinical study for its proprietary B019 injection. B019 is a chimeric antigen receptor (CAR) autologous T cell injection that targets CD19…
-
Shanghai Pharmaceuticals Posts 13.11% YOY Revenue Growth in Q3 2023 Financials
•
China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has released its financial results for the third quarter of 2023. The company recorded RMB 197.508 billion (USD 27 billion) in revenues over the nine-month period, marking a 13.11% year-on-year (YOY) increase. For Q3 alone, revenues reached RMB 64.9…
-
Shanghai Pharmaceuticals Partners with Asymchem for Advanced Drug Development and Production
•
China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a strategic partnership with compatriot firm Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a leading Contract Development and Manufacturing Organization (CDMO). This collaboration will span synthetic biotechnology, continuous reaction technology, and the development and production of…
-
SciClone Pharmaceuticals Partners with Shanghai Pharmaceutical and Menarini Group
•
China’s SciClone Pharmaceuticals Inc. (HKG: 6600) has entered into a collaborative agreement with Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) and Italy-headquartered Menarini Group. While specific details of the partnership remain undisclosed, this alliance marks a significant step for all parties involved. Focus on Oncology and Infectious Diseases SciClone is dedicated…
-
Shanghai Pharma Health Commerce Secures $68M in Series C Funding Round
•
Shanghai Pharma Health Commerce Co., Ltd, a distinguished former subsidiary of China’s pharmaceutical giant Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607), has reportedly secured RMB 500 million (USD 68 million) in a Series C financing round. This substantial investment underscores the company’s robust growth and potential within the healthcare sector.…
